Buoyed by ever-faster sequencing abilities, scientists are making headway in understanding cancer genomics. But, William Sellers told the audience at the American Association of Cancer Research meeting this week, as impressive as genomic advances have been, "most known genetic alterations have not led directly to drug candidates."